TLDR Biotech

TLDR Biotech
Archive
Page 17

The Latest Biotech & Pharma Updates

Jun 25, 2024

Biotech & Pharma Updates | June 22 - 24, 2024

Alnylam’s slam dunk Ph3 heart disease data, Pfizer tapped to supply RSV vaccine to the UK, Novo Nordisk shares detailed hemophilia A Ph3 data, Novo Nordisk earmarks $4.1B for NC manufacturing plant, and Merck KGaA cuts a Ph3 cancer trial short

Anis Fahandej-Sadi

Jun 24, 2024

Biotech & Pharma Updates | June 20 - 23, 2024

BMS & Takeda both land colorectal cancer approvals, don't doze on Eli Lilly's sleep apnea data, Tectonic goes IPO via reverse merger, Vertex signs reimbursement deal with NHS, while Ginkgo Bioworks cuts 150+ jobs

Anis Fahandej-Sadi

Jun 22, 2024

📈📉 Biotech & Pharma Stock Market Recap | June 17 - 21, 2024

🧬 Winners, Losers, and Upcoming Earnings Calls

Anis Fahandej-Sadi

Jun 21, 2024

Biotech & Pharma Updates | June 18 - 20, 2024

Sapreta Therapeutics lands key DMD label expansion, Gilead's twice-yearly HIV prevention med scores 100% efficacy, iOnctura raises $86M, Takeda drops $230M on a facility expansion, and Bora makes US-based sterile manufacturing moves

Anis Fahandej-Sadi

Jun 19, 2024

Biotech & Pharma Updates | June 17 - 18, 2024

GSK has a double Ph3 win, Marea Therapeutics launches with $190M to go after remnant cholesterol, Hikma buys multiple assets and sites from Xeliia Pharmaceuticals, and Sanofi and Roche both sign big drug development partnership

Anis Fahandej-Sadi

Jun 18, 2024

Biotech & Pharma Updates | June 16 - 17, 2024

AstraZeneca & Merck both land FDA approvals for endometrial cancer, Takeda's epilepsy bet is up in flames, Merck lands a historic vaccine approval, and a BioNTech and MediLink Therapeutics ADC gets an FDA partial hold

Anis Fahandej-Sadi

Jun 17, 2024

Biotech & Pharma Updates | June 13 - 16, 2024

Vertex releases positive long term gene therapy data, Vaxart lands a big BARDA contract, AI drug discovery debuts on Hong Kong stock exchange, Kyverna has a rough week due to autoimmune data and 100% of something for two cancer biotechs

Anis Fahandej-Sadi

Jun 15, 2024

📈📉 Biotech & Pharma Stock Market Recap | June 10 - 14, 2024

🧬 Winners, Losers, and Upcoming Earnings Calls

Anis Fahandej-Sadi

Jun 14, 2024

Biotech & Pharma Updates | June 12 - 13, 2024

Pfizer's DMD hopes shattered in Ph3 (while also planning for 8 blockbusters by 2030), while JP Morgan closes $500M biotech fund, a new antibody player launches with $168M, and Eli Lilly gets an upgrade (from accelerated to full approval)

Anis Fahandej-Sadi

Jun 13, 2024

Biotech & Pharma Updates | June 11 - 12, 2024

BMS still has an M&A appetite, Ultragenyx has some bone-building Ph2/3 results, Eli Lilly's Alzheimer's approval could be good news for rivals Biogen and Eisai too, Foresite Capital raises a $900M life science fund, and Pfizer signs a discovery pact with ProFound Therapeutics in search of the next great obesity med

Anis Fahandej-Sadi

Jun 12, 2024

Biotech & Pharma Updates | June 10 - 11, 2024

Syntis Bio to take on GLP-1 giants, Ipsen's new FDA approval, an ADC and an "ADC-like" company both raise millions, cancer patient groups like AstraZeneca, and Pfizer takes an M&A break

Anis Fahandej-Sadi

Jun 11, 2024

Biotech & Pharma Updates | June 9 - 10, 2024

Eli Lilly gets full support from FDA advisory panel, GSK's RSV vaccine gets a label expansion, Moderna’s flu/covid combo passes Ph3, Amber Therapeutics raises $100M, Alumis plans an IPO, and the FDA gets curious about AI

Anis Fahandej-Sadi

First Back

13 14 15 16 17 18 19 20

Next Last